Accessibility Menu
Hangzhou Tigermed Consulting logo

Hangzhou Tigermed Consulting(SEHK) 3347

Market CapHK$34.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-64%
5 Year-71%
1 Year-18%
1 Month+5%
HK$40.18
-2.38%
-0.98Today
Hangzhou Tigermed Consulting last closing stock price
MetricPriceDate
Last closeHKD 39.562026-09-01
Hangzhou Tigermed Consulting stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.69%HKD 40.242026-08-25
1 month+4.88%HKD 37.722026-07-31
3 month+21.87%HKD 32.462026-06-03
Year to date-7.01%HKD 42.542025-12-31
1 year-17.72%HKD 48.082025-09-01
3 year-7.46%HKD 42.752023-08-31
5 year-70.54%HKD 134.302021-09-02
Since inception-63.55%HKD 107.662020-08-07

Hangzhou Tigermed Consulting Financials at a Glance

Market Cap

HK$34.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥7.28B

Net Income (TTM)

CN¥93.15M

EPS (TTM)

HK$0.07

P/E Ratio

613.41

Dividend

HK$0.14

Beta (Volatility)

-0.08 (Low)

Price

HK$40.18

Volume

1,363,500

Open

HK$41.16

Previous Close

HK$41.16

Daily Range

HK$39.34 - HK$41.24

52-Week Range

HK$28.12 - HK$57.00

Estimated Earnings Date

Oct 22, 2026

3347 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd. is a leading provider of clinical research services, specializing in the development of pharmaceutical and health-related products. Founded in 2004 and headquartered in Hangzhou, China, the company offers a comprehensive range of services, including clinical trial management and data analysis.

Products and Services
  • Clinical trial management for phases I to IV
  • Data management and analysis services
  • Regulatory support for clinical trial registration
Growth Outlook
  • Revenue of CNY 1.8 billion reported in Q1 2026
  • Consistent revenue growth observed over the past four quarters
  • Strong demand for clinical research services in the biotechnology sector
Financial Highlights
  • Net income of CNY 49 million in Q1 2026
  • Operating income margin of 22.5% in the latest quarter
  • Current ratio of 2.30 indicates strong liquidity position
Hangzhou Tigermed Consulting Co., Ltd. has established itself as a key player in the biotechnology industry, providing essential services that support the development of new medical products. The company has demonstrated robust financial performance, with a notable revenue of CNY 1.8 billion in the first quarter of 2026, reflecting a strong demand for its services. The operating income margin of 22.5% indicates effective cost management and operational efficiency. The growth outlook remains positive, driven by increasing investments in clinical research and a growing pipeline of pharmaceutical products. The company’s strong liquidity position, as evidenced by a current ratio of 2.30, provides a solid foundation for future expansion and investment opportunities. Overall, Hangzhou Tigermed Consulting Co., Ltd. presents a compelling case for potential investors interested in the biotechnology sector.
AI Generated • Aug 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

11,130

CEO

Zeng Yu Wen

Website

www.tigermed.net

Headquarters

Hangzhou, ZH 310051, CN

3347 Financials

Key Financial Metrics (TTM)

Gross Margin

25.85%

Operating Margin

16.39%

Net Income Margin

1.25%

Return on Equity

0.44%

Return on Capital

4.50%

Return on Assets

0.33%

Earnings Yield

0.16%

Dividend Yield

0.35%

Payout Ratio

95.33%

Stock Overview

Market Cap

HK$34.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

834.17M

Volume

1.36M

Avg. Volume

2.05M

Financials (TTM)

Gross Profit

CN¥1.88B

Operating Income

CN¥1.19B

EBITDA

CN¥1.83B

Operating Cash Flow

CN¥1.42B

Capital Expenditure

-CN¥221.64M

Free Cash Flow

CN¥1.20B

Cash & ST Invst.

CN¥2.15B

Total Debt

CN¥2.35B

Hangzhou Tigermed Consulting Performance Analysis

Hangzhou Tigermed Consulting annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 8,217,861,44631.2%
20232023-12-31CNY 8,135,206,277-1.0%
20242024-12-31CNY 7,138,599,853-12.3%
20252025-12-31CNY 7,390,609,6203.5%
Hangzhou Tigermed Consulting sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.3%
Q42025-12-311.8%
Q12026-03-31-0.3%
Q22026-06-305.4%
Hangzhou Tigermed Consulting annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 2.70-32.2%
20232023-12-31CNY 2.59-4.1%
20242024-12-31CNY 0.51-80.4%
20252025-12-31CNY 1.13121.5%
Hangzhou Tigermed Consulting sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30196.0%
Q42025-12-31-120.3%
Q12026-03-31140.0%
Q22026-06-30-1016.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.90B

+12.6%

Gross Profit

CN¥507.10M

-0.2%

Gross Margin

26.72%

N/A

Market Cap

HK$34.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$3.08M

N/A

Employees

11,130

N/A

Net Income

-CN¥460.24M

-311.2%

EBITDA

CN¥313.32M

+1.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥2.15B

+18.1%

Total Debt

CN¥2.35B

-1.5%

Accounts Receivable

CN¥4.20B

+1.0%

Inventory

CN¥65.61M

+50.4%

Long Term Debt

CN¥1.93B

+105.3%

Short Term Debt

CN¥413.24M

-71.3%

Return on Assets

0.33%

N/A

Return on Invested Capital

4.74%

N/A

Free Cash Flow

CN¥191.11M

+21.0%

Operating Cash Flow

CN¥247.54M

+17.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 3347

What is the current price of Hangzhou Tigermed Consulting?

Hangzhou Tigermed Consulting is trading at HK$40.18 per share.

What is the 52-week range for Hangzhou Tigermed Consulting?

Over the past 52 weeks, Hangzhou Tigermed Consulting has traded between HK$28.12 and HK$57.00.

How much debt does Hangzhou Tigermed Consulting have?

As of the most recent reporting period, Hangzhou Tigermed Consulting reported total debt of CN¥2.71B.

How much cash does Hangzhou Tigermed Consulting have on hand?

Hangzhou Tigermed Consulting reported CN¥2.37B in cash and cash equivalents in its most recent financial results.

What is Hangzhou Tigermed Consulting’s dividend yield?

Hangzhou Tigermed Consulting currently has a dividend yield of 0.35%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services